Rituximab-CHOP Induced Interstitial Pneumonitis in Patients with Disseminated Extranodal Marginal Zone B Cell Lymphoma.
10.3349/ymj.2008.49.1.155
- Author:
Kwang Min KIM
1
;
Ho Cheol KIM
;
Kyung Nyeo JEON
;
Hoon Gu KIM
;
Jung Hun KANG
;
Jong Ryeal HAHM
;
Gyeong Won LEE
Author Information
1. Department of Internal Medicine, College of Medicine, Gyeongsang National University, Jinju, Korea. brightree@lycos.co.kr
- Publication Type:Case Report
- Keywords:
Interstitial pneumonitis;
rituximab;
lymphoma
- MeSH:
Aged;
Antibodies, Monoclonal/*adverse effects/*therapeutic use;
Antineoplastic Combined Chemotherapy Protocols/*adverse effects/*therapeutic use;
Biopsy;
Cyclophosphamide/adverse effects/therapeutic use;
Doxorubicin/adverse effects/therapeutic use;
Humans;
Lung Diseases, Interstitial/*chemically induced/*pathology/radiography/surgery;
Lymphoma, B-Cell, Marginal Zone/*drug therapy;
Male;
Prednisone/adverse effects/therapeutic use;
Tomography, X-Ray Computed;
Vincristine/adverse effects/therapeutic use
- From:Yonsei Medical Journal
2008;49(1):155-158
- CountryRepublic of Korea
- Language:English
-
Abstract:
A 69-year-old male was diagnosed in February 2004 with stage IV extranodal marginal zone B cell lymphoma involving the mediastinal nodes, lung parenchyma and bone marrow with high LDH. Shortness of breath developed following the 5th course of Rituximab-CHOP chemotherapy (cyclophosphamide, Vincristine, Doxorubicin, Prednisolone). Bronchoscopy guided transbronchial lung biopsy revealed interstitial thickening and type II pneumocyte activation, compatible with interstitial pneumonitis. After treatment with prednisolone a complete resolution of the dyspnea was observed. The patient was well on routine follow-up at the outpatient clinic, with no progression of lymphoma or interstitial pneumonitis.
